Total amount raised
$233.9 Millions
Latest funding date
Location
TraceLink has successfully raised funds through multiple rounds, with the latest being a Series D round closed on August 21, 2018. The company is backed by nine investors, including Volition Capital and Georgian.
TraceLink's platform leverages a vast digital network to provide end-to-end supply chain orchestration, focusing on the healthcare and life sciences industries. Keep reading to explore the intricacies of TraceLink's fundraising journey and the investors backing this innovative platform.
What Is TraceLink?
TraceLink, founded in 2009, is a company based in North Reading, Massachusetts. It operates within the developer platform, SaaS, and supply chain management industries. The company was founded by Lucy Deus and Shabbir Dahod.
Specializing in digitalizing end-to-end supply chains, TraceLink focuses on the healthcare and life sciences sectors. The company employs between 501 and 1000 people and has a global presence with offices across North America, South America, Europe, and Asia.
How Much Funding Has TraceLink Raised?
- Series A
- Amount Raised: $5.5M
- Date: February 2014
- Lead Investors: FirstMark
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop and launch their SaaS platform for supply chain management.
- Series B
- Amount Raised: $20.2M
- Date: February 2015
- Lead Investors: Volition Capital
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand their platform capabilities and increase market reach.
- Series C
- Amount Raised: $51.5M
- Date: November 2016
- Lead Investors: GS Growth
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop and expand TraceLink's platform to meet growing regulatory requirements and market demand.
- Series D
- Amount Raised: $60M
- Date: June 2018
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the company's growth and enhance its supply chain orchestration solutions.
- Series D
- Amount Raised: $93M
- Date: August 2018
- Lead Investors: Georgian
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To continue expanding TraceLink's capabilities in helping pharmaceutical companies comply with the Drug Supply Chain Security Act and to prepare for a potential public offering.
Total Amount Raised: $230.2M
Current Valuation: Not publicly disclosed
Key Investors
- Georgian
- Details: Georgian is a growth equity firm that invests in high-growth software companies. They focus on companies leveraging applied artificial intelligence, trust, and conversational AI.
- Investment Focus Areas: Software, artificial intelligence, conversational AI
- Notable Investments: Shopify, FreshBooks, Top Hat
- GS Growth
- Details: GS Growth is a division of Goldman Sachs that invests in high-growth companies. They have a broad investment portfolio across various sectors.
- Investment Focus Areas: Technology, healthcare, consumer services
- Notable Investments: Uber, Spotify, Pinterest
- Volition Capital
- Details: Volition Capital focuses on high-growth, founder-owned companies. They invest primarily in the software, internet, and consumer sectors.
- Investment Focus Areas: Software, internet, consumer
- Notable Investments: Chewy, Assent Compliance, Connatix
- FirstMark
- Details: FirstMark is an early-stage venture capital firm. They invest in technology companies with a focus on SaaS, consumer, and healthcare sectors.
- Investment Focus Areas: SaaS, consumer, healthcare
- Notable Investments: Pinterest, Shopify, Riot Games
- F-Prime Capital
- Details: F-Prime Capital is a venture capital firm that focuses on healthcare and technology sectors. They have a history of investing in innovative companies.
- Investment Focus Areas: Healthcare, technology
- Notable Investments: Moderna, Ultragenyx
What's Next for TraceLink?
TraceLink stands at the cusp of significant opportunities, driven by the increasing importance of drug traceability and compliance with regulatory measures like the Drug Supply Chain Security Act. The company's recent $93 million Series D funding round underscores the vast potential in this sector. As TraceLink prepares for a potential public offering, the financial metrics reveal a robust growth trajectory, with a 62% year-over-year increase in second-quarter revenue.
Future fundraising opportunities appear promising, bolstered by the company's strong financial performance and the growing demand for SaaS platforms in the pharmaceutical industry. However, TraceLink may face challenges such as navigating varying country-specific regulatory requirements and competition from other track-and-trace solution providers. Ensuring the scalability and reliability of their platform will be crucial as they expand into new markets and regions.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like TraceLink and gather other critical business insights.
Sign up for free to start transforming your sales strategy today.
